http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004087643-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 |
| filingDate | 2003-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c0222c752a4f8e32087efadeeaaf8ee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1536a581b91d9116834360c89c40355e |
| publicationDate | 2004-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2004087643-A1 |
| titleOfInvention | Method of treating thrombocytopenic purpura and hemolytic uremic syndrome |
| abstract | The present invention provides a method of treatment of thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) with protein C. The claimed invention provides a needed therapy for a potentially serious and debilitating disorder while avoiding complications such as bleeding tendency, toxicity and general side effects of plasma exchange or currently available anti-coagulant agents. |
| priorityDate | 1998-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 95.